Sign in →

Test Code SEAFP Seafood Allergen Profile, Serum

Reporting Name

Seafood Allergen Profile

Useful For

Establishing a diagnosis of an allergy to seafood

 

Defining the allergen responsible for eliciting signs and symptoms

 

Identifying allergens:

-Responsible for allergic response and/or anaphylactic episode

-To confirm sensitization prior to beginning immunotherapy

-To investigate the specificity of allergic reactions to insect venom allergens, drugs, or chemical allergens

Profile Information

Test ID Reporting Name Available Separately Always Performed
COD Codfish, IgE Yes Yes
CRAB Crab, IgE Yes Yes
SHRI Shrimp, IgE Yes Yes
TUNA Tuna, IgE Yes Yes
LOB Lobster, IgE Yes Yes

Method Name

Fluorescence Enzyme Immunoassay (FEIA)

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum


Ordering Guidance


For a listing of allergens available for testing, see Allergens - Immunoglobulin E (IgE) Antibodies in Special Instructions



Specimen Required


Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial 

Specimen Volume: 0.7 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  90 days

Reject Due To

Gross hemolysis OK
Gross lipemia OK

Reference Values

Class

IgE kU/L

Interpretation

0 

<0.10 

Negative 

0/1 

0.10-0.34 

Borderline/equivocal 

1 

0.35-0.69 

Equivocal 

2 

0.70-3.49 

Positive 

3 

3.50-17.4 

Positive 

4 

17.5-49.9 

Strongly positive 

5 

50.0-99.9 

Strongly positive 

6 

≥100 

Strongly positive 

 

Reference values apply to all ages.

Day(s) Performed

Monday through Friday

CPT Code Information

86003 x 5

LOINC Code Information

Test ID Test Order Name Order LOINC Value
SEAFP Seafood Allergen Profile 49222-3

 

Result ID Test Result Name Result LOINC Value
COD Codfish, IgE 6082-2
CRAB Crab, IgE 6092-1
LOB Lobster, IgE 6165-5
SHRI Shrimp, IgE 6246-3
TUNA Tuna, IgE 6270-3

Clinical Information

Clinical manifestations of immediate hypersensitivity (allergic) diseases are caused by the release of proinflammatory mediators (histamine, leukotrienes, and prostaglandins) from IgE-sensitized effector cells (mast cells and basophils) when cell-bound IgE antibodies interact with an allergen.

 

In vitro serum testing for IgE antibodies provides an indication of the immune response to allergen that may be associated with allergic disease.

 

The allergens chosen for testing often depend upon the age of the patient, history of allergen exposure, season of the year, and clinical manifestations. In individuals predisposed to develop allergic disease, the sequence of sensitization and clinical manifestations proceed as follows: eczema and respiratory disease (rhinitis and bronchospasm) in infants and children younger than 5 years of age due to food sensitivity (milk, egg, soy, and wheat proteins), followed by respiratory disease (rhinitis and asthma) in older children and adults due to sensitivity to inhalant allergens (dust mites, mold, and pollen inhalants).

Interpretation

Detection of IgE antibodies in serum (class 1 or greater) indicates an increased likelihood of allergic disease as opposed to other etiologies and defines the allergens that may be responsible for eliciting signs and symptoms.

 

The level of IgE antibodies in serum varies directly with the concentration of IgE antibodies expressed as a class score or kU/L.

Cautions

Testing for IgE antibodies is not useful in patients previously treated with immunotherapy to determine if residual clinical sensitivity exists, or in patients in whom the medical management does not depend upon identification of allergen specificity.

 

Some individuals with clinically insignificant sensitivity to allergens may have measurable levels of IgE antibodies in serum, and test results must be interpreted in the clinical context.

 

False-positive results for IgE antibodies may occur in patients with markedly elevated serum IgE (>2500 kU/L) due to nonspecific binding to allergen solid phases.

Method Description

Specific IgE from the patient's serum reacts with the allergen of interest, which is covalently coupled to an ImmunoCAP. After washing away nonspecific IgE, enzyme-labeled anti-IgE antibody is added to form a complex. After incubation, unbound anti-IgE is washed away, and the bound complex incubated with a developing agent. After stopping the reaction, the fluorescence of the eluate is measured. Fluorescence is proportional to the amount of specific IgE present in the patient's sample (ie, the higher the fluorescence value, the more IgE antibody is present).(Package insert: ImmunoCAP System Specific IgE FEIA. Phadia; Rev 06/2020)

Report Available

Same day/1 to 3 days

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.